Skip to main content Skip to search Skip to main navigation

Latest News from PIC/S

From 6 to 7 November 2023, the PIC/S Committee Meeting took place in Bangkok, Thailand, chaired by Paul Gustafson from Health Canada. The Ministry of Public Health of the Thai Food and Drug Administration (Thai FDA) hosted the meeting.

The meeting was attended by 37 of the 56 Participating Authorities (PAs) as well as various applicants, pre-applicants and partner organisations.

The most important aspects in brief:

DFA submits application for pre-accession

  • The Egyptian Medicines Agency EDA applied for PIC/S pre-accession on 22 September 2023.
  • This step involves an assessment by the PIC/S to identify potential discrepancies between the PIC/S membership requirements and the applicant regulatory authority's system. The PIC/S Committee then decides on further steps, e.g. on a possible application for membership.
  • The appointment of the rapporteur, who accompanies and supervises the pre-accession process, takes place via a written procedure.

China's NMPA has applied for membership

  • On 22 September 2023, China's National Medical Products Administration (NMPA) submitted its application for the PIC/S membership, which was completed on 3 November 2023. The pre-accession procedure was initiated on 24 September 2021.
  • The regulatory authority represents all Chinese authorities that participate in the Chinese Good Manufacturing Practice Regulatory Compliance Programme (GMPRCP) of the PIC/S.
  • Jacques Morénas from the French authority ANSM has been appointed as rapporteur. He will lead the PIC/S audit team overseeing the accession process.

Memorandum of Understanding with the ICH

  • In October 2023, a Memorandum of Understanding (MoU) between the PIC/S and the International Council for Harmonisation (ICH) was signed.
  • The MoU aims to ease the cooperation on ICH guidelines of relevance to inspection activities and to provide training for assessors and inspectors.
  • As both organisations are active in the field of harmonisation of medicinal products, it is not the first rapprochement. The PIC/S holds observer status with the ICH since 2017, and many ICH regulatory members are themselves PAs with the PIC/S.

A new PIC/S chair for the period 2024-2025 was also elected at the committee meeting in early November. The committee voted unanimously for Mr Jacques Morénas.


Source:

PIC/S: Newsroom

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next